Théoneste Umumararungu, Jean Baptiste Nyandwi, Jonathan Katandula, Eric Twizeyimana, Jean Claude Tomani, Noël Gahamanyi, Nestor Ishimwe, Emmanuel Oladayo Olawode, Gratien Habarurema, Matabishi Mpenda, Jeanne Primitive Uyisenga, Shamsaldeen Ibrahim Saeed
Bioorganic & medicinal chemistry 2024 Sep 01Human Immunodeficiency Virus (HIV) is the causative agent of Acquired Immunodeficiency Syndrome (AIDS) with high morbidity and mortality rates. Treatment of AIDS/HIV is being complicated by increasing resistance to currently used antiretroviral (ARV) drugs, mainly in low- and middle-income countries (LMICs) due to drug misuse, poor drug supply and poor treatment monitoring. However, progress has been made in the development of new ARV drugs, targeting different HIV components (Fig. 1). This review aims at presenting and discussing the progress made towards the discovery of new ARVs that are at different stages of clinical trials as of July 2024. For each compound, the mechanism of action, target biomolecule, genes associated with resistance, efficacy and safety, class, and phase of clinical trial are discussed. These compounds include analogues of nucleoside reverse transcriptase inhibitors (NRTIs) - islatravir and censavudine; non-nucleoside reverse transcriptase inhibitors (NNRTIs) - Rilpivirine, elsulfavirine and doravirine; integrase inhibitors namely cabotegravir and dolutegravir and chemokine coreceptors 5 and 2 (CC5/CCR2) antagonists for example cenicriviroc. Also, fostemsavir is being developed as an attachment inhibitor while lenacapavir, VH4004280 and VH4011499 are capsid inhibitors. Others are maturation inhibitors such as GSK-254, GSK3532795, GSK3739937, GSK2838232, and other compounds labelled as miscellaneous (do not belong to the classical groups of anti-HIV drugs or to the newer classes) such as obefazimod and BIT225. There is a considerable progress in the development of new anti-HIV drugs and the effort will continue since HIV infections has no cure or vaccine till now. Efforts are needed to reduce the toxicity of available drugs or discover new drugs with new classes which can delay the development of resistance. Copyright © 2024 Elsevier Ltd. All rights reserved.
Théoneste Umumararungu, Jean Baptiste Nyandwi, Jonathan Katandula, Eric Twizeyimana, Jean Claude Tomani, Noël Gahamanyi, Nestor Ishimwe, Emmanuel Oladayo Olawode, Gratien Habarurema, Matabishi Mpenda, Jeanne Primitive Uyisenga, Shamsaldeen Ibrahim Saeed. Current status of the small molecule anti-HIV drugs in the pipeline or recently approved. Bioorganic & medicinal chemistry. 2024 Sep 01;111:117860
PMID: 39094527
View Full Text